Glucosyl hesperidin lowers serum triglyceride level in hypertriglyceridemic subjects through the improvement of very low-density lipoprotein metabolic abnormality.
To examine the serum triglyceride (TG)-lowering effect of a soluble hesperidin derivative, glucosyl hesperidin (G-hesperidin), and its mechanisms, we carried out a G-hesperidin administration test in hypertriglyceridemic subjects. G-Hesperidin was administered to the subjects at 500 mg/d for 24 wk. In this study, the subjects were classified into high-TG type (TG > 150 mg/dL), borderline-TG type (TG 110-150 mg/dL) and normal-TG type (TG < 110 mg/dL) on the basis of their initial serum TG values. Among these phenotypes, serum TG level significantly decreased in the high-TG type during the G-hesperidin administration period. It was also observed that elevated values of serum remnant-like particle cholesterol (RLP-C), apolipoprotein (apo) B, apo C-II, apo C-III and apo E occurred in the high-TG type and that these serum levels were significantly reduced by G-hesperidin administration. Moreover, polyacrylamide gel electrophoresis analysis of serum lipoproteins revealed that the very low-density lipoprotein (VLDL)/low-density lipoprotein (LDL) ratio and LDL migration index of the high-TG type were remarkably higher than those of the other phenotypes but that their high values were significantly reduced by the administration. These results indicate that G-hesperidin preferentially lowers serum TG in hypertriglyceridemic subjects and that this effect is possibly caused by the improvement of VLDL metabolic abnormality, leading to the reduction of small dense LDL.
Miwa
Yoshikatsu
Y
Hayashibara Biochemical Laboratories, Inc., 1-2-3 Shimoishii, Okayama 700-0907, Japan.
Mitsuzumi
Hitoshi
H
Sunayama
Takahiro
T
Yamada
Mika
M
Okada
Katsuhide
K
Kubota
Michio
M
Chaen
Hiroto
H
Mishima
Yasuo
Y
Kibata
Masayoshi
M
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001053:Apolipoproteins / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005960:Glucosides / Q000008:administration & dosage*; D006569:Hesperidin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000145:classification / Q000188:drug therapy*; D008074:Lipoproteins / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood*; D008875:Middle Aged; D010316:Particle Size; D010641:Phenotype; D014280:Triglycerides / Q000097:blood*; D005723:gamma-Glutamyltransferase / Q000097:blood
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D005960:Glucosides; D008074:Lipoproteins; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D014280:Triglycerides; C112017:remnant-like particle cholesterol; C487382:glucosyl hesperidin; D002784:Cholesterol; D006569:Hesperidin; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase